Darren W. Davis, Ph.D.
Founder, President & CEO
Dr. Darren Davis is a biotechnology executive and visionary leader with more than twenty-five years of distinguished biotechnology and clinical translational research experience. Dr. Davis founded ApoCell in 2004 to commercialize innovative “liquid biopsy” solutions that help accelerate the biopharma decision making process for efficient and economical advancement of drug candidates to the regulated clinical market. He achieved global market expansion through the establishment of subsidiary businesses in Europe and China to support the ApoStream technology development and customer demands for its products. Dr. Davis has a successful track record in building high-performing leadership teams with a global services presence. He developed a proprietary rare cell technology, ApoStream, in collaboration with the National Cancer Institute. Dr. Davis is leading a team of scientists and engineers to develop the ApoStream into a point-of-care regulated medical device. He led ApoCell to achieve dynamic growth and recognition, with placement on the “Inc 500 / 5000 List of America’s Fastest Growing Companies” for three consecutive years, the Houston Business Journal’s “Fast 100” and Deloitte’s “Technology Fast 500.” Dr. Davis is the author and co-author of over 100 peer-reviewed publications. Dr. Davis received his doctorate from the University of Texas Health Science Center School of Biomedical Sciences and M.D. Anderson Cancer Center, Houston, TX.
Chairman of the Board
David McWilliams has served as Director since 2004. From 2004 to 2008, Mr. McWilliams served as President and Chief Executive Officer of Opexa. In 2003, Mr. McWilliams served as President and Chief Executive Officer of Bacterial Barcodes, Inc., a molecular diagnostics company. Mr. McWilliams currently serves as a Director of Novelos Therapeutics, Inc., and on the boards of ApoCell and Norwell, a cancer therapeutics company. Mr. McWilliams received an MBA in Finance from the University of Chicago and a B.A. in chemistry, Phi Beta Kappa, from Washington and Jefferson College.
Thomas H. Jennings
Thomas Jennings has served as Director since 2009. Mr. Jennings is Managing Director at Summit Partners, whom he joined in 1997. Prior to Summit, he worked as a consultant with Andersen Consulting (now Accenture). Mr. Jennings has served as a director of numerous software, technology, healthcare, and life sciences companies. He is currently a Director of ApoCell, AvePoint, Fermentas, and Telerik. He is actively involved with Summit’s investments in IMMCO Diagnostics, NameMedia, and NetWitness Corporation. Mr. Jennings holds an AB in economics and theology from Boston College, where he received the Scholar of the College award.
William J. Doré, Jr.
William J. Doré, Jr. has served as Director since 2005. From 2000 to 2006, Mr. Doré served as Vice President, Investor Relations at Global Industries, Ltd., overseeing capital fundraising activities, communications to the investment community and corporate communications, including marketing. Mr. Doré has spent the past 20 years in the oil services sector including serving on the executive management team for Doré Energy Corporation. Mr. Doré currently operates a private equity fund and serves on various corporate boards.
Rick L. Ryan, Ph.D.
Dr. Rick Ryan has been in the Biotech/Life Science industry for 30 years. Rick was the Vice President of the Drug Discovery & Development business unit at Millipore from 2006-2010, where he was responsible for the development and commercialization of products and services (both new chemical entities and biotherapeutics) for biopharma customers. He also led cross-divisional innovation initiatives to support the development of biomarkers and stem cells for drug discovery / development applications. He was formerly the President of LINCO Research, Inc., which was acquired by Serologicals in May 2006, followed immediately by Millipore’s acquisition in July 2006. For the 20 years prior to LINCO and Millipore, Rick held several technology and business management positions at Embrex (VP Commercial Development – Animal Vaccines), Purina Mills (VP Biotechnology Development) and Monsanto Company. During his 15 years at Monsanto he held several positions, including Director of Commercial / Business Development, Director of Strategic Planning, and Director of International Markets. Rick received his Ph.D. in Biochemistry from the University of Illinois and his MBA from Washington University. He retired from Millipore in December 2010, and recently formed The Winfield Group, a life sciences consulting firm with a focus on strategic development of new technology and services for biopharma and biomedical applications.